Kennedy J T
Laryngoscope. 1975 May;85(5):806-22. doi: 10.1288/00005537-197505000-00005.
In vitro, colony inhibition tests using lymphocytes and serum from 42 patients with other carcinomas, and 12 control patients with no carcinoma, were performed using cultured target cells (CALI). Target cell colony counts were significantly diminished by lymphocytes of 2 of 12 (16.7 percent) patients with no cancer, compared with those 26 of 42 (61.9 percent) patients with epidermoid carcinoma. An unexpected finding was significant colony inhibition of lymphocytes of 23 of 27 (85.2 percent) patients tested within 24 months of diagnosis of carcinoma compared with significant inhibition in only 3 of 15 (20 percent) patients tested after 24 months of diagnosis of carcinoma. Serum blocking factor was found in 9 of 42 (21.4 percent) patients with epidermoid carcinoma. It was found on follow-up that four of these nine (44.4 percent) had later recurrent or new tumors compared to recurrence or new tumor incidence of only 6 of 33 (18.2 percent) patients with no serum blocking factor present in the serum.
在体外,使用培养的靶细胞(CALI)对42例其他癌症患者和12例无癌症的对照患者的淋巴细胞和血清进行了集落抑制试验。与42例(61.9%)表皮样癌患者中的26例相比,12例(16.7%)无癌症患者中的2例患者的淋巴细胞显著降低了靶细胞集落计数。一个意外发现是,在癌症诊断后24个月内进行检测的27例患者中有23例(85.2%)的淋巴细胞出现显著集落抑制,而在癌症诊断后24个月后进行检测的15例患者中只有3例(20%)出现显著抑制。在42例(21.4%)表皮样癌患者中发现了血清阻断因子。随访发现,这9例中有4例(44.4%)后来出现复发或新肿瘤,而血清中不存在血清阻断因子的33例患者中只有6例(18.2%)出现复发或新肿瘤。